The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

The myeloma stem cell concept, revisited: from phenomenology to operational terms

(2016) H. E. Johnsen et al.   HAEMATOLOGICA

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

The myeloma stem cell concept, revisited: from phenomenology to operational terms

(2016) H. E. Johnsen et al.   HAEMATOLOGICA

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

(2015) X. Liu et al.   CANCER RESEARCH

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

(2015) Alfred L. Garfall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells

(2014) J. Chu et al.   CLINICAL CANCER RESEARCH

Current treatment landscape for relapsed and/or refractory multiple myeloma

(2014) Meletios A. Dimopoulos et al.   Nature Reviews Clinical Oncology

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Tumour heterogeneity and cancer cell plasticity

(2013) Corbin E. Meacham et al.   NATURE

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy

(2012) H. K. Gan et al.   CANCER RESEARCH

Identification, Characterization, and Epitope Mapping of Human Monoclonal Antibody J19 That Specifically Recognizes Activated Integrin α4β7

(2012) JunPeng Qi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Crystal structure of α5β1 integrin ectodomain: Atomic details of the fibronectin receptor

(2012) Masamichi Nagae et al.   JOURNAL OF CELL BIOLOGY

T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma

(2012) Kevin KH Chow et al.   MOLECULAR THERAPY

Integrin  7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion

(2011) P. Neri et al.   BLOOD

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

(2011) S. Terakura et al.   BLOOD

CD48 as a novel molecular target for antibody therapy in multiple myeloma

(2011) Naoki Hosen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of multiple myeloma

(2011) S. Vincent Rajkumar   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

(2009) T. P. J. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nonmuscle myosin heavy chain IIA mediates integrin LFA-1 de-adhesion during T lymphocyte migration

(2008) Nicole A. Morin et al.   JOURNAL OF EXPERIMENTAL MEDICINE